

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer: updated overall survival and subgroup analyses of the open-label, phase 3 TRIBE study

Lancet Oncology, The

16, 1306-1315

DOI: [10.1016/s1470-2045\(15\)00122-9](https://doi.org/10.1016/s1470-2045(15)00122-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	TRIBE study: are all three cytotoxic drugs crucial? Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e578-e579.	5.1	0
3	Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 75.	1.0	5
4	TRIBE study: are all three cytotoxic drugs crucial?. <i>Lancet Oncology</i> , The, 2015, 16, e577.	5.1	1
5	New hope on the horizon for patients with metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2015, 4, 229-239.	0.8	0
6	Role of targeted therapy in metastatic colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 642.	0.8	80
7	Survival benefit and safety of the combinations of FOLFOXIRI & plus m; bevacizumab versus the combinations of FOLFIRI & plus m; bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4833-4842.	1.0	15
8	Front-Line Treatment of Metastatic Colorectal Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 1231-1233.	2.5	1
9	Role of Biologics in First-Line Treatment of Colorectal Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 1219-1228.	2.5	32
10	BRAF Mutation in Colorectal Cancer. , 0, , .		1
11	Targeting angiogenesis in gastrointestinal tumors: current challenges. <i>Translational Gastroenterology and Hepatology</i> , 2016, 1, 67-67.	1.5	15
12	RAS and BRAF in metastatic colorectal cancer management. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 687-704.	0.6	56
13	How the Lab is Changing Our View of Colorectal Cancer. <i>Tumori</i> , 2016, 102, 541-547.	0.6	15
14	Allied therapies against <i>BRAF</i> -mutated advanced colon cancer: the right plans to win the battle. <i>Colorectal Cancer</i> , 2016, 5, 53-55.	0.8	1
15	Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. <i>Annals of Oncology</i> , 2016, 27, 1746-1753.	0.6	204
16	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
17	Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease. <i>ESMO Open</i> , 2016, 1, e000084.	2.0	9
18	Management of BRAF-mutant metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2016, 5, 131-133.	0.8	2
19	Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 361-369.	1.1	26

#	ARTICLE	IF	CITATIONS
20	Biomarker in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 156-164.	1.0	35
21	Differential Radiographic Appearance of BRAFV600E Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1536-1543.	2.3	17
23	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. <i>Annals of Oncology</i> , 2016, 27, 1456-1466.	0.6	51
24	The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 233-244.	1.1	29
25	Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 264-272.	0.6	2
26	Oral drugs in the treatment of metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1351-1361.	0.9	21
27	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1306-1314.	1.9	36
28	Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. <i>Visceral Medicine</i> , 2016, 32, 178-183.	0.5	32
30	Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC). <i>Scientific Reports</i> , 2016, 6, 34006.	1.6	16
32	Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 303-313.	1.0	0
33	Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. <i>Digestive Diseases</i> , 2016, 34, 574-579.	0.8	26
34	Multidisciplinary management of stage IV colon cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2016, 27, 213-218.	0.2	2
35	Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 97-104.	3.4	8
36	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 557-571.	1.1	7
37	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. <i>Annals of Oncology</i> , 2016, 27, 843-849.	0.6	46
38	Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 117-126.	2.0	1
39	A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2016, 11, 293-308.	1.7	18
40	Monoclonal antibodies for treating gastric cancer: promises and pitfalls. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 759-769.	1.4	6

#	ARTICLE	IF	CITATIONS
41	Reply to G. Nasti and A. Ottaiano and to A. Avallone and A. Budillon. <i>Journal of Clinical Oncology</i> , 2016, 34, 1565-1566.	0.8	2
42	Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 135-140.	1.0	28
43	Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. <i>Clinical Colorectal Cancer</i> , 2016, 15, 7-15.	1.0	3
44	Antibodies for Treatment of Metastatic Colorectal Cancer. , 2017, , 217-244.		0
45	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
46	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1453-1486.	0.8	255
47	Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 81-90.	1.0	0
48	BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 9.	1.3	51
49	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 625-657.	1.2	75
50	Molecular Biomarkers for the Evaluation of Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 187-225.	1.2	108
51	High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. <i>Oncology Reports</i> , 2017, 37, 785-792.	1.2	64
52	Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. <i>British Journal of Cancer</i> , 2017, 116, 1271-1278.	2.9	55
53	A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. <i>Seminars in Oncology</i> , 2017, 44, 24-33.	0.8	12
54	FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases. <i>Acta Oncologica</i> , 2017, 56, 646-652.	0.8	8
55	Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. <i>Annals of Oncology</i> , 2017, 28, 1713-1729.	0.6	654
56	Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. <i>International Journal of Colorectal Disease</i> , 2017, 32, 1179-1190.	1.0	96
57	A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. <i>British Journal of Cancer</i> , 2017, 116, 1279-1286.	2.9	37
58	North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. <i>Cancer</i> , 2017, 123, 3494-3501.	2.0	32

#	ARTICLE	IF	CITATIONS
59	Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 54-60.	3.4	99
60	Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. , 2017, , 1-16.		0
61	Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. <i>European Journal of Cancer</i> , 2017, 79, 50-60.	1.3	114
62	Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. <i>Oncologist</i> , 2017, 22, 728-736.	1.9	10
63	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. <i>European Journal of Cancer</i> , 2017, 81, 26-35.	1.3	13
64	FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, e170278.	3.4	152
65	Molecular Biomarkers for the Evaluation of Colorectal Cancer. <i>American Journal of Clinical Pathology</i> , 2017, 147, 221-260.	0.4	32
66	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	183
67	FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, 405-409.e2.	1.0	11
68	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 709-721.	1.4	85
70	From tumour heterogeneity to advances in precision treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 235-246.	12.5	466
71	Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. <i>Annals of Oncology</i> , 2017, 28, 562-568.	0.6	132
73	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2017, 73, 74-84.	1.3	54
75	Second-Line Therapy for Advanced Colorectal Cancer: EGFR vs. Continuation of VEGF Inhibition. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 411-418.	1.0	0
76	Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. <i>Annals of Oncology</i> , 2017, 28, 2629-2630.	0.6	3
77	Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). <i>European Journal of Cancer</i> , 2017, 84, 262-269.	1.3	8
78	FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land. <i>Cancer Letters</i> , 2017, 408, 71-72.	3.2	1
79	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. <i>Cancer Treatment Reviews</i> , 2017, 60, 109-119.	3.4	45

#	ARTICLE	IF	CITATIONS
80	How and when adjuvant treatment should be intensified in stage III colorectal cancers?. <i>Future Oncology</i> , 2017, 13, 1999-2006.	1.1	2
81	Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 54-62.	2.0	54
82	Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging. <i>Angiogenesis</i> , 2017, 20, 547-555.	3.7	26
83	Long-term outcomes of patients with 10 or more colorectal liver metastases. <i>British Journal of Cancer</i> , 2017, 117, 604-611.	2.9	58
84	BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. <i>Annals of Oncology</i> , 2017, 28, 2648-2657.	0.6	227
85	Next generation sequencing of progressive colorectal liver metastases after portal vein embolization. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 351-361.	1.7	4
86	S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. <i>ESMO Open</i> , 2017, 2, e000135.	2.0	17
87	Recent developments in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 551-564.	1.4	82
88	Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 1357-1366.	0.8	6
89	Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer. <i>Oncology Letters</i> , 2017, 14, 2491-2498.	0.8	4
90	The potential role of nintedanib in treating colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1153-1162.	0.9	15
91	Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. <i>Annals of Oncology</i> , 2017, 28, 2128-2134.	0.6	61
92	Microenvironmental regulation of tumour angiogenesis. <i>Nature Reviews Cancer</i> , 2017, 17, 457-474.	12.8	1,299
94	Personalizing Maintenance Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 205-211.	1.0	1
95	Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2017, 17, 38.	1.1	21
96	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	1.1	28
97	Selective internal radiation therapy in untreated patients with unresectable liver dominant metastatic colorectal cancer. <i>Future Oncology</i> , 2017, 13, 205-207.	1.1	0
98	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 580-590.	0.3	2

#	ARTICLE	IF	CITATIONS
99	Hepatic Arterial Infusion for Unresectable Liver Metastases from Colorectal Cancer: The Dawn of a New Era?. <i>Annals of Surgical Oncology</i> , 2017, 24, 6-7.	0.7	7
100	Continuum of care strategy in metastatic colorectal cancer: a review. <i>Colorectal Cancer</i> , 2017, 6, 95-103.	0.8	0
101	Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	466
104	Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1522.	1.8	23
105	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.	1.4	91
106	Immunotherapy for Colorectal Cancer. <i>Cancers</i> , 2017, 9, 50.	1.7	125
108	Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. <i>Chinese Journal of Cancer</i> , 2017, 36, 81.	4.9	13
109	Chemotherapies and future directions in metastatic colorectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 141-145.	0.3	0
110	Identifying CT-Based Risk Factors Associated with Synchronous Liver Metastases in Colorectal Cancer. <i>Journal of the Korean Society of Radiology</i> , 2017, 77, 286.	0.1	0
111	Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil. <i>Cancer Management and Research</i> , 2017, Volume 9, 461-469.	0.9	8
112	A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy. <i>Global & Regional Health Technology Assessment</i> , 2017, 4, grhta.5000274.	0.2	2
113	Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 246-256.	1.8	20
114	Biologics in bowel cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 449-456.	0.6	4
117	Heat shock protein 27 knockdown using nucleotide–based therapies enhances sensitivity to 5-FU chemotherapy in SW480 human colon cancer cells. <i>Oncology Reports</i> , 2018, 39, 1119-1124.	1.2	6
118	Atezolizumab for the treatment of colorectal cancer: <i>the latest evidence and clinical potential</i>. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 449-457.	1.4	25
119	Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1229-1254.	1.6	263
120	Surgical Strategy Based on Indocyanine Green Test for Chemotherapy-Associated Liver Injury and Long-Term Outcome in Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1077-1088.	0.9	11
121	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. <i>Annals of Oncology</i> , 2018, 29, 1528-1534.	0.6	83

#	ARTICLE	IF	CITATIONS
122	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e471-e488.	1.0	12
123	Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases. <i>British Journal of Surgery</i> , 2018, 105, 1200-1209.	0.1	16
124	What Chemotherapy to Recommend in Metastatic Patients?. , 2018, , 339-348.		0
125	Recent advances in treatment for colorectal liver metastasis. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 167-175.	1.2	36
126	A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. <i>Clinical Colorectal Cancer</i> , 2018, 17, 231-239.e7.	1.0	42
127	Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San Jos��, Costa Rica, August 2016. <i>ESMO Open</i> , 2018, 3, e000315.	2.0	10
128	The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 69-77.	2.0	17
129	Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial. <i>European Journal of Radiology</i> , 2018, 100, 124-129.	1.2	2
130	An Update on Colorectal Cancer. <i>Current Problems in Surgery</i> , 2018, 55, 76-116.	0.6	20
131	The evolving management of small bowel adenocarcinoma. <i>Acta Oncol��gica</i> , 2018, 57, 712-722.	0.8	28
132	Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?. <i>European Radiology</i> , 2018, 28, 2058-2067.	2.3	177
133	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 251-266.	1.1	41
134	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO��ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2018, 29, 44-70.	0.6	432
135	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. <i>Annals of Oncology</i> , 2018, 29, 924-930.	0.6	99
136	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. <i>European Journal of Cancer</i> , 2018, 96, 115-124.	1.3	2
137	Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. <i>Future Oncology</i> , 2018, 14, 1629-1645.	1.1	22
139	Clinical Trials and Progress in Metastatic Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 349-365.	0.6	64
140	A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. <i>International Journal of Oncology</i> , 2018, 52, 1391-1400.	1.4	7

#	ARTICLE	IF	CITATIONS
141	Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. <i>Methods in Molecular Biology</i> , 2018, 1765, 281-297.	0.4	12
142	Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. <i>ESMO Open</i> , 2018, 3, e000297.	2.0	18
143	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	2.9	17
144	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1-34.	1.0	1,187
145	Biomarker-driven and molecular targeted therapies for colorectal cancers. <i>Seminars in Oncology</i> , 2018, 45, 124-132.	0.8	9
146	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e69-e76.	1.0	44
147	Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to KRA1hne Prognostic Category and BRAF Mutation Status. <i>Clinical Colorectal Cancer</i> , 2018, 17, 50-57.e8.	1.0	6
148	Impact of Metastasectomy in the Multimodality Approach for <i>BRAF</i> V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. <i>Oncologist</i> , 2018, 23, 128-134.	1.9	34
149	Prognostic influence of hepatic margin after resection of colorectal liver metastasis: role of modern preoperative chemotherapy. <i>International Journal of Colorectal Disease</i> , 2018, 33, 71-78.	1.0	18
150	Systemic Therapy for Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 235-242.	0.6	113
151	Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 1521-1537.	1.2	5
152	Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. <i>Oncotarget</i> , 2018, 9, 18698-18711.	0.8	127
153	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , 2018, 36, 674-681.	0.8	70
154	Transplantation for colorectal metastases: on the edge of a revolution. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 74-74.	1.5	13
155	Antiangiogenic Therapy in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 165-170.	1.0	77
156	Phase II Trial of Neoadjuvant Chemotherapy using Triplet without Radiotherapy for Borderline Resectable Advanced Rectal Cancer in Japan (NEUTRAL Trial). <i>Journal of Clinical Trials</i> , 2018, 08, .	0.1	0
157	Recent advances in understanding colorectal cancer. <i>F1000Research</i> , 2018, 7, 1528.	0.8	14
159	Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study. <i>Neoplasia</i> , 2018, 20, 1219-1226.	2.3	21

#	ARTICLE	IF	CITATIONS
160	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial. <i>Frontiers in Oncology</i> , 2018, 8, 474.	1.3	13
161	Circulating Levels of Osteopontin Predict Patients' Outcome after Resection of Colorectal Liver Metastases. <i>Journal of Clinical Medicine</i> , 2018, 7, 390.	1.0	12
162	<i>KRAS</i> , <i>NRAS</i> and <i>BRAF</i> mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. <i>Oncotarget</i> , 2018, 9, 26279-26290.	0.8	20
163	How the <i>BRAF</i> V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-14.	0.7	34
164	Role of Tyrosine Kinases in Gastrointestinal Malignancies. , 2018, , .		1
165	Functional Consequences and Clinical Significance of Tyrosine Kinase Inhibitors in Advanced Colorectal Cancer. , 2018, , 115-140.		0
166	Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2018, 16, 200.	0.8	3
167	FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. <i>European Journal of Cancer</i> , 2018, 104, 108-116.	1.3	17
168	Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles. <i>Oncotarget</i> , 2018, 9, 16477-16488.	0.8	23
169	Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 100.	0.7	13
170	Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 53-65.	2.0	12
171	Colorectal Cancer: Why Does Side Matter?. <i>Drugs</i> , 2018, 78, 789-798.	4.9	41
172	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	1.3	29
173	Session 2: Mutational discordance: the big challenge in personalized treatments – any solutions?. <i>Colorectal Disease</i> , 2018, 20, 49-51.	0.7	1
174	Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. <i>British Journal of Cancer</i> , 2018, 119, 170-175.	2.9	6
175	Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2018, 13, 447-459.	1.7	13
176	Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial. <i>Clinical Colorectal Cancer</i> , 2018, 17, 285-296.	1.0	37
177	First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 441.	1.6	9

#	ARTICLE	IF	CITATIONS
178	Emerging treatment options for BRAF-mutant colorectal cancer. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2018, Volume 8, 13-23.	5.5	55
179	First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. <i>European Journal of Cancer</i> , 2018, 101, 263-272.	1.3	58
180	Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-21.	0.7	60
181	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 991-1006.	1.1	44
182	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403.	2.0	20
183	Palliative Management for Advanced Colorectal Cancer. , 2018, , 407-414.		0
184	First-line molecular therapies in the treatment of metastatic colorectal cancer – a literature-based review of phases II and III trials. <i>Innovative Surgical Sciences</i> , 2018, 3, 85-86.	0.4	6
185	Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. <i>Scientific Reports</i> , 2018, 8, 7386.	1.6	12
186	The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2298.	1.8	4
187	Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 1870-1881.	1.1	14
188	Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. <i>Clinical Colorectal Cancer</i> , 2018, 17, e733-e739.	1.0	7
189	Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. <i>Cancer</i> , 2018, 124, 3118-3126.	2.0	23
190	The Role of Biosimilars in Patient Access to Therapeutic Antibodies for Immune Mediated Inflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6779-6783.	0.9	6
191	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2018, 13, e0193640.	1.1	5
192	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. <i>British Journal of Cancer</i> , 2018, 118, 1609-1616.	2.9	47
193	Pro- and antiangiogenic therapies: current status and clinical implications. <i>FASEB Journal</i> , 2019, 33, 34-48.	0.2	56
194	Multiple treatment lines and prognosis in metastatic colorectal cancer patients. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 307-313.	2.7	38
195	Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 83.	1.3	21

#	ARTICLE	IF	CITATIONS
197	Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis â€œ Better Treatment?. <i>Visceral Medicine</i> , 2019, 35, 259-265.	0.5	5
198	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the â€˜BRAF BeCoolâ€™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
199	Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 238-244.	1.0	29
200	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019, 45, 139-154.	2.7	36
201	Beppu's Nomogram Score Is an Independent Prognostic Factor for Colorectal Liver Metastasis Receiving Perioperative Chemotherapy and/or Targeted Therapy. <i>In Vivo</i> , 2019, 33, 1301-1306.	0.6	7
202	Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness. <i>BMC Cancer</i> , 2019, 19, 687.	1.1	15
203	BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGE0 RASANC Study. <i>Cancers</i> , 2019, 11, 998.	1.7	22
204	Initial systemic chemotherapeutic and targeted therapy strategies for the treatment of colorectal cancer patients with liver metastases. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1767-1775.	0.9	12
205	BRAF Mutation and Its Importance in Colorectal Cancer. , 0, , .		11
206	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019, 79, 1375-1394.	4.9	48
207	Exploring the best treatment options for BRAF-mutant metastatic colon cancer. <i>British Journal of Cancer</i> , 2019, 121, 434-442.	2.9	54
208	Molecular targeted therapy of <i>BRAF</i>-mutant colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985649.	1.4	72
210	Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice. <i>BMC Cancer</i> , 2019, 19, 960.	1.1	7
211	Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. <i>Cancers</i> , 2019, 11, 1558.	1.7	25
212	FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). <i>Journal of Clinical Oncology</i> , 2019, 37, 3401-3411.	0.8	132
213	Use of perioperative chemotherapy in colorectal cancer metastatic to the liver. <i>Gastroenterology Report</i> , 2019, 7, 301-311.	0.6	16
214	BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5369.	1.8	88
215	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1189.	1.7	4

#	ARTICLE	IF	CITATIONS
216	Advances in the therapy of BRAF ^{V600E} metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2019, 19, 823-829.	1.1	5
218	Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers. Medical Sciences (Basel, Switzerland), 2019, 7, 100.	1.3	26
220	Surgical Resection of Colorectal Cancer With Distant Metastases to Other than Liver or Lung. In Vivo, 2019, 33, 1605-1608.	0.6	3
221	RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance. PLoS ONE, 2019, 14, e0222392.	1.1	19
222	Is progression in the future liver remnant a contraindication for second-stage hepatectomy?. Hpb, 2019, 21, 1478-1484.	0.1	2
223	Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer. Acta Oncologica, 2019, 58, 326-333.	0.8	3
224	Current Status of Maintenance Systemic Therapies in Metastatic Colorectal Cancer: 2018 Update. Current Colorectal Cancer Reports, 2019, 15, 28-35.	1.0	1
225	Treatment sequencing in metastatic colorectal cancer. European Journal of Cancer, 2019, 109, 70-83.	1.3	215
226	Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer. European Radiology, 2019, 29, 3871-3880.	2.3	11
227	<p>Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study<p>. Cancer Management and Research, 2019, Volume 11, 4357-4369.	0.9	17
228	Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. American Journal of Clinical Pathology, 2019, 152, 97-108.	0.4	36
229	MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer. Targeted Oncology, 2019, 14, 285-293.	1.7	11
230	Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984642.	1.4	7
231	Mechanisms of immunogenicity in colorectal cancer. British Journal of Surgery, 2019, 106, 1283-1297.	0.1	32
232	BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report. Case Reports in Oncology, 2019, 12, 426-429.	0.3	0
233	Efficacy of palliative chemotherapy in elderly patients with colorectal cancer. Zeitschrift Fur Gastroenterologie, 2019, 57, 484-490.	0.2	0
234	Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program. European Journal of Surgical Oncology, 2019, 45, 1870-1875.	0.5	4
235	Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). International Journal of Clinical Oncology, 2019, 24, 1223-1230.	1.0	9

#	ARTICLE	IF	CITATIONS
236	BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. <i>British Journal of Surgery</i> , 2019, 106, 1237-1247.	0.1	33
237	Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 307-313.	1.1	9
238	Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 137.	1.8	13
239	Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. <i>Cancer Medicine</i> , 2019, 8, 3120-3130.	1.3	2
240	Emergency Surgical Management of Colorectal Cancer. <i>Hot Topics in Acute Care Surgery and Trauma</i> , 2019, , .	0.1	2
241	Postoperative Oncologic Management of Colorectal Cancer Emergencies. <i>Hot Topics in Acute Care Surgery and Trauma</i> , 2019, , 233-239.	0.1	0
242	<p>Weekly alternate intensive regimen FlrB/FOx in metastatic colorectal cancer patients: an update from clinical practice</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2159-2170.	1.0	8
243	Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1719-1728.	1.2	8
244	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). <i>Journal of Clinical Oncology</i> , 2019, 37, 1876-1885.	0.8	169
245	Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 588.	1.7	42
246	FOLFOXIRI plus biologics in advanced colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 411-422.	1.4	4
247	Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. <i>Cancers</i> , 2019, 11, 369.	1.7	4
248	Lesion detection performance of an abbreviated gadoxetic acid-enhanced MRI protocol for colorectal liver metastasis surveillance. <i>European Radiology</i> , 2019, 29, 5852-5860.	2.3	19
249	Phase <sc>II</sc> trial of aflibercept with <sc>FOLFIRI</sc> as a second-line treatment for Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2019, 110, 1032-1043.	1.7	30
250	GSTP1 as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy. <i>Oncology Letters</i> , 2019, 17, 2897-2904.	0.8	7
251	Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study. <i>Oncotarget</i> , 2019, 10, 1070-1084.	0.8	7
252	Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. <i>Journal of Surgical Oncology</i> , 2019, 119, 642-652.	0.8	28
253	Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 53-60.	1.0	4

#	ARTICLE	IF	CITATIONS
254	Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer. <i>International Journal of Cancer</i> , 2019, 145, 2488-2495.	2.3	17
255	Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study XELAVIRI (AIO KKK0110). <i>Journal of Clinical Oncology</i> , 2019, 37, 22-32.	0.8	35
256	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1460-1469.	0.8	188
257	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. <i>Journal of Surgical Oncology</i> , 2019, 119, 564-582.	0.8	55
258	The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591882029.	1.4	12
259	The Developing Story of Predictive Biomarkers in Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2019, 9, 12.	1.1	111
260	First-line therapy for metastatic colorectal cancer: Current perspectives and future directions. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 3-14.	0.7	4
261	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000813.	2.0	49
262	Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000590.	2.0	1
263	Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). <i>Oncologist</i> , 2019, 24, 921-932.	1.9	51
264	BRAF mutant metastatic colorectal cancers: new arrows in our quiver. <i>Annals of Translational Medicine</i> , 2019, 7, S367-S367.	0.7	1
265	The evolving treatment paradigm for BRAF V600 mutant colorectal cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S257-S257.	0.7	1
266	Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019, 24, e1331-e1340.	1.9	20
267	Rare case of triple mutant (KRAS + NRAS + BRAF) metastatic colon adenocarcinoma. <i>BMJ Case Reports</i> , 2019, 12, e221816.	0.2	4
268	Health and Economic Impact of Intensive Surveillance for Distant Recurrence After Curative Treatment of Colon Cancer: A Mathematical Modeling Study. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 872-881.	0.7	4
269	Anti-angiogenesis treatment in a patient with appendix metastasis of small cell lung cancer. <i>Medicine (United States)</i> , 2019, 98, e15333.	0.4	2
270	Darmkrebs - Aktuelle Standards und Perspektiven in der Therapie. <i>Karger Kompass Onkologie</i> , 2019, 6, 73-74.	0.0	0
271	Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment. <i>PLoS ONE</i> , 2019, 14, e0225938.	1.1	18

#	ARTICLE	IF	CITATIONS
272	Apatinib as an optional treatment in metastatic colorectal cancer. <i>Medicine (United States)</i> , 2019, 98, e16919.	0.4	13
273	Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond. <i>Current Oncology</i> , 2019, 26, 33-42.	0.9	7
274	An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone. <i>Anti-Cancer Drugs</i> , 2019, 30, 428-430.	0.7	1
275	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	1
276	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , 2019, 49, 446-454.	0.5	12
277	Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation. <i>Clinical Colorectal Cancer</i> , 2019, 18, e251-e260.	1.0	12
278	CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer. <i>Oncology</i> , 2019, 96, 156-163.	0.9	6
279	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	1.0	7
280	Recent Advances in the Treatment of Colorectal Cancer. , 2019, , .		2
281	Chemotherapy for Metastatic Colorectal Cancer. , 2019, , 101-111.		1
282	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 523-534.	0.9	3
283	Neuroimmune Semaphorin 4A in Cancer Angiogenesis and Inflammation: A Promoter or a Suppressor?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 124.	1.8	16
284	Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival. <i>Surgery</i> , 2019, 165, 703-711.	1.0	7
285	Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis. <i>Clinical and Translational Oncology</i> , 2019, 21, 443-450.	1.2	9
286	A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 183-189.	2.9	38
287	Feasibility of "Watch-and-Wait" Management before Repeat Hepatectomy for Colorectal Liver Metastases. <i>Digestive Surgery</i> , 2019, 36, 233-240.	0.6	3
288	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1-42.	1.0	1,123
289	Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. <i>Internal Medicine Journal</i> , 2020, 50, 165-172.	0.5	1

#	ARTICLE	IF	CITATIONS
290	Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. <i>Cancer Gene Therapy</i> , 2020, 27, 235-245.	2.2	42
291	Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 387-400.	0.6	6
292	Biomarker-guided therapy for colorectal cancer: strength in complexity. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 11-32.	12.5	195
293	Feasibility and Safety of CT-Guided High-Dose-Rate Brachytherapy Combined with Transarterial Chemoembolization Using Irinotecan-Loaded Microspheres for the Treatment of Large, Unresectable Colorectal Liver Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 315-322.	0.2	6
294	Colorectal cancer peritoneal metastases: Biology, treatment and next steps. <i>European Journal of Surgical Oncology</i> , 2020, 46, 675-683.	0.5	5
295	Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia. <i>Oncology and Therapy</i> , 2020, 8, 161-169.	1.0	1
296	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , 2020, 26, 1372-1384.	3.2	66
297	Passive Monoclonal and Polyclonal Antibody Therapies. , 2020, , 251-348.		9
298	Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments. <i>Cancers</i> , 2020, 12, 2663.	1.7	3
299	Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial. <i>Cancers</i> , 2020, 12, 2752.	1.7	3
300	Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report. <i>Clinical Colorectal Cancer</i> , 2021, 20, e96-e99.	1.0	5
301	Incidence of Asymptomatic Brain Metastases in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 263-269.	1.0	12
302	Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer. <i>Journal of International Medical Research</i> , 2020, 48, 030006052093044.	0.4	0
303	Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases. <i>European Journal of Cancer</i> , 2020, 138, 89-98.	1.3	13
304	An Odyssey into the Land of Deleterious Rare Mutations in Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 3115-3117.	0.7	3
305	Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan. <i>Annals of Surgical Oncology</i> , 2020, 27, 3307-3315.	0.7	20
306	Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112540.	2.6	6
308	Current therapy of advanced colorectal cancer according to RAS/RAF mutational status. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1143-1157.	2.7	19

#	ARTICLE	IF	CITATIONS
310	Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review. <i>European Journal of Cancer</i> , 2020, 141, 225-238.	1.3	29
311	Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 1116.	1.1	2
312	<p>Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 601-617.	0.4	6
313	The Role of BRAF in Metastatic Colorectal Carcinomaâ€œPast, Present, and Future. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9001.	1.8	8
314	A retrospective analysis of emergency surgery for cases of acute abdomen during cancer chemotherapy. Case series. <i>Annals of Medicine and Surgery</i> , 2020, 57, 143-147.	0.5	5
315	Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review. <i>Advances in Therapy</i> , 2020, 37, 4233-4248.	1.3	5
316	<p>Past, Present, and Future of Anticancer Nanomedicine</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5719-5743.	3.3	23
317	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 2645-2660.	1.1	1
318	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683.	1.1	53
319	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 687.	1.1	9
320	Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 277-284.	1.1	4
321	Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for <i>RAS</i> Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3175-3184.	0.8	76
322	Predictors of outcome in elderly patients with metastatic colorectal cancer: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment. <i>Anti-Cancer Drugs</i> , 2020, 31, 518-522.	0.7	3
323	Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated â€œ NIVACOR trial (GOIRC-03-2018). <i>BMC Cancer</i> , 2020, 20, 822.	1.1	13
324	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. <i>Pharmacoeconomics</i> , 2020, 38, 1263-1275.	1.7	3
325	Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition. <i>Cancer Science</i> , 2020, 111, 3962-3969.	1.7	18
326	A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer. <i>Cancer Medicine</i> , 2020, 9, 7558-7571.	1.3	9
327	The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 932-939.	0.6	1

#	ARTICLE	IF	CITATIONS
328	Serum Gamma Glutamyl transferase is a predictor of recurrence after R0 hepatectomy for patients with colorectal cancer liver metastases. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094797.	1.4	4
329	Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2020, 15, 567-577.	1.7	14
330	Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. <i>Anti-Cancer Drugs</i> , 2020, 31, 856-865.	0.7	2
331	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3314-3324.	0.8	139
332	The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis. <i>Annals of Surgical Oncology</i> , 2020, 27, 4263-4270.	0.7	24
333	Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). <i>European Journal of Cancer</i> , 2020, 138, 19-29.	1.3	21
334	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. <i>Cancers</i> , 2020, 12, 3236.	1.7	23
336	FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÅš-1 trial. <i>ESMO Open</i> , 2020, 5, e000944.	2.0	32
337	Efficacy of ⁹⁰ Y-Radioembolization in Metastatic Colorectal Cancer Depending on the Primary Tumor Side. <i>Digestive Diseases</i> , 2021, 39, 351-357.	0.8	3
338	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1214.	1.7	26
339	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020, 123, 403-409.	2.9	93
340	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1513-1527.	1.0	7
341	TRIBE2 results and toxicity. <i>Lancet Oncology</i> , The, 2020, 21, e298.	5.1	0
342	Investigation of the role and mechanism of ARHGAP5-mediated colorectal cancer metastasis. <i>Theranostics</i> , 2020, 10, 5998-6010.	4.6	16
343	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>Translational Oncology</i> , 2020, 13, 100795.	1.7	26
344	The effect of primary tumor radiotherapy in patients with Unresectable stage IV Rectal or Rectosigmoid Cancer: a propensity score matching analysis for survival. <i>Radiation Oncology</i> , 2020, 15, 126.	1.2	6
345	Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). <i>Clinical Colorectal Cancer</i> , 2020, 19, 285-290.	1.0	5
346	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	1.3	10

#	ARTICLE	IF	CITATIONS
347	Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 89-95.	1.0	1
348	Population-based Screening for <i>BRAF</i> V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. <i>Clinical Cancer Research</i> , 2020, 26, 4599-4605.	3.2	26
350	Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model. <i>Journal of Clinical Medicine</i> , 2020, 9, 1687.	1.0	5
351	<i>BRAF</i> Mutated Colorectal Cancer: New Treatment Approaches. <i>Cancers</i> , 2020, 12, 1571.	1.7	44
352	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 653-664.	1.5	7
353	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in <i>KRAS</i> wild-type colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 9778.	1.6	5
354	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. <i>Clinical Colorectal Cancer</i> , 2020, 19, 165-177.	1.0	15
355	<i>KRAS</i> G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. <i>Clinical Colorectal Cancer</i> , 2020, 19, 219-225.	1.0	45
356	Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. <i>British Journal of Cancer</i> , 2020, 123, 518-524.	2.9	16
357	Treatment options in <i>BRAF</i> -mutant metastatic colorectal cancer. <i>Anti-Cancer Drugs</i> , 2020, 31, 545-557.	0.7	7
358	Current treatment options in <i>RAS</i> mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2077-2087.	1.2	10
359	Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected. <i>Clinical Colorectal Cancer</i> , 2020, 19, e110-e116.	1.0	20
360	Successful treatment of metastatic colorectal cancer with synchronous <i>BRAF</i> V600E mutation and dMMR with BGB-A317. <i>Immunotherapy</i> , 2020, 12, 229-234.	1.0	0
361	FOLFOXIRI reintroduction in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2020, 21, 468-469.	5.1	3
362	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	5.1	196
363	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
364	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 251-270.	1.1	4
365	Decoding the Genomic Report for Radiologists. <i>American Journal of Roentgenology</i> , 2020, 214, 949-961.	1.0	0

#	ARTICLE	IF	CITATIONS
366	Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22.	7.1	853
367	Redefining Colorectal Cancer by Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 147-159.	1.8	9
368	Efficacy and Safety of Modified FOLFOXIRI+Î± in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience. <i>Internal Medicine</i> , 2020, 59, 1239-1245.	0.3	0
369	CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup. <i>Frontiers in Oncology</i> , 2020, 10, 8.	1.3	35
370	TRIBE2 results and toxicity â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e300-e301.	5.1	0
371	Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer. <i>Neoplasia</i> , 2020, 22, 365-375.	2.3	7
372	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , 2020, 12, 1742.	1.7	4
373	Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer. <i>World Journal of Surgical Oncology</i> , 2020, 18, 163.	0.8	3
374	ASO Author Reflections: The Moment That BRAF V600E Mutation Starts Evolving into â€œPrecision Oncosurgeryâ€œin Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 3316-3317.	0.7	3
375	Predicting Chemotherapy Toxicity and Death in Older Adults with Colon Cancer: Results of MOST Study. <i>Oncologist</i> , 2020, 25, e85-e93.	1.9	30
376	Bevacizumabâ€œassociated intestinal perforation and perioperative complications in patients receiving bevacizumab. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 151-155.	1.2	11
377	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020, 46, 955-966.	0.5	22
378	Encorafenib, binimetinib and cetuximab combined therapy for patients with <i>BRAFV600E</i> mutant metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 161-173.	1.1	9
379	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020, 122, 957-962.	2.9	4
380	Administration sequence for multi-agent oncolytic regimens. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 933-942.	0.5	1
381	CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer. <i>Cells</i> , 2020, 9, 124.	1.8	5
382	The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. <i>Cancer Cell International</i> , 2020, 20, 30.	1.8	63
383	Phase II study of 5-fluorouracilâ€œleucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802). <i>International Journal of Clinical Oncology</i> , 2020, 25, 1291-1298.	1.0	5

#	ARTICLE	IF	CITATIONS
385	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , 2020, 12, 1022.	1.7	16
387	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. <i>Pharmacoeconomics</i> , 2020, 38, 683-713.	1.7	10
388	Improvements in Clinical Outcomes for <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4435-4441.	3.2	17
389	Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals: results from the South Australian Metastatic Colorectal Cancer Registry. <i>Internal Medicine Journal</i> , 2021, 51, 69-77.	0.5	1
390	Effect of Time to Surgery of Colorectal Liver Metastases on Survival. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 169-176.	0.6	10
391	Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data. <i>International Journal of Cancer</i> , 2021, 148, 296-306.	2.3	27
392	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100637.	1.0	11
393	An appraisal of emerging second line therapies for metastatic colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 165-179.	1.4	2
394	Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). <i>European Journal of Surgical Oncology</i> , 2021, 47, 89-100.	0.5	16
395	What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey. <i>World Journal of Surgery</i> , 2021, 45, 822-830.	0.8	3
396	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	3.4	2
397	Multidisciplinary Treatment of Colorectal Cancer. , 2021, , .		2
399	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021, 26, 302-309.	1.9	9
400	A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). <i>International Journal of Clinical Oncology</i> , 2021, 26, 399-408.	1.0	5
401	Cardiac hemodynamic response to the 6-minute walk test in patients with intestinal carcinoma undergoing bevacizumab treatment. <i>Annals of Palliative Medicine</i> , 2021, 10, 1362-1369.	0.5	1
402	Controversies in the treatment of <i>RAS</i> wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 827-839.	1.2	3
403	New advances in the clinical management of <i>RAS</i> and <i>BRAF</i> mutant colorectal cancer patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 65-79.	1.4	4
404	Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a real-world multi-institution cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 84-93.	0.7	7

#	ARTICLE	IF	CITATIONS
405	Molecular subtypes of colorectal cancer: AnÂemerging therapeutic opportunity for personalized medicine. <i>Genes and Diseases</i> , 2021, 8, 133-145.	1.5	71
406	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 137.	1.7	46
407	Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience. <i>Vojnosanitetski Pregled</i> , 2022, 79, 796-804.	0.1	2
408	Kolon. , 2021, , 209-270.		0
409	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. <i>Clinical Cancer Research</i> , 2021, 27, 2159-2167.	3.2	9
410	Importance of Systemic Chemotherapy in Advanced Peritoneal Metastasis. , 2021, , 239-253.		0
411	ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm. <i>Cancers</i> , 2021, 13, 346.	1.7	46
412	BRAF Mutation in Colorectal Cancer: An Enigmatic Target. <i>Journal of Clinical Oncology</i> , 2021, 39, 259-261.	0.8	8
413	FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Leftâ€Sided RAS / BRAF Wildâ€Ttype Colorectal Cancer: Which â€œSideâ€Are You On?. <i>Oncologist</i> , 2021, 26, 277-280.	1.9	1
414	Targeting KRAS in Colorectal Cancer. <i>Current Oncology Reports</i> , 2021, 23, 28.	1.8	24
415	Defining and Targeting BRAF Mutations in Solid Tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 30.	1.3	25
416	Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. <i>Clinical and Translational Oncology</i> , 2021, 23, 1520-1528.	1.2	4
417	Nanomedicines in the treatment of colon cancer: a focus on metallodrugs. <i>Drug Delivery and Translational Research</i> , 2022, 12, 49-66.	3.0	20
418	Diagnosis and Treatment of Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 669.	3.8	941
419	Current Status of Biologics in Perioperative Treatment for Resectable or Borderline Resectable Liver Metastases. <i>Current Colorectal Cancer Reports</i> , 2021, 17, 10-22.	1.0	0
420	BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. <i>Targeted Oncology</i> , 2021, 16, 227-236.	1.7	2
421	Molecular Oncology in Management of Colorectal Cancer. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 169-180.	0.3	0
422	Study of oxaliplatin penetration into ovaries of patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of colorectal and appendiceal origin using mass spectrometry imaging. <i>Pleura and Peritoneum</i> , 2021, 6, 67-74.	0.5	5

#	ARTICLE	IF	CITATIONS
424	UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI. <i>Journal of Oncology</i> , 2021, 2021, 1-9.	0.6	11
425	BRAF V600E mutated metastatic colorectal cancer: current progress and future directions. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1311-1313.	1.4	1
426	Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 602194.	1.3	9
427	Combined Systemic and Hepatic Artery Infusion Pump Chemo-Therapy as a Liver-Directed Therapy for Colorectal Liver Metastasis-Review of Literature and Case Discussion. <i>Cancers</i> , 2021, 13, 1283.	1.7	7
428	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021, 146, 74-83.	1.3	29
429	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	2.3	758
430	Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). <i>European Journal of Cancer</i> , 2021, 147, 128-139.	1.3	9
431	Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. <i>ESMO Open</i> , 2021, 6, 100073.	2.0	12
432	Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. <i>BMC Cancer</i> , 2021, 21, 354.	1.1	1
433	Therapeutic implications of B-RAF mutations in colorectal cancer. <i>Journal of Visceral Surgery</i> , 2021, 158, 487-496.	0.4	5
435	Occurrence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab. <i>Oncotarget</i> , 2021, 12, 1046-1056.	0.8	4
436	Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). <i>BJS Open</i> , 2021, 5, .	0.7	7
437	Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients. <i>Materials</i> , 2021, 14, 2440.	1.3	14
438	Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? <i>Expert Opinion on Clinical Practice. Frontiers in Oncology</i> , 2021, 11, 637823.	1.3	8
439	Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials. <i>Cancer Treatment Reviews</i> , 2021, 96, 102177.	3.4	29
440	Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. <i>Current Medicinal Chemistry</i> , 2021, 28, 3158-3172.	1.2	1
441	Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1846-e1855.	1.4	9
442	Ascorbic acid analogue 6-Deoxy-6-[18F] fluoro-L-ascorbic acid as a tracer for identifying human colorectal cancer with SVCT2 overexpression. <i>Translational Oncology</i> , 2021, 14, 101055.	1.7	4

#	ARTICLE	IF	CITATIONS
444	Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer. <i>Advances in Oncology</i> , 2021, 1, 297-310.	0.1	0
445	FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 564.	1.1	3
446	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021, 11, 12191.	1.6	3
447	Liver transplantation for advanced liver-only colorectal metastases. <i>British Journal of Surgery</i> , 2021, 108, 1402-1405.	0.1	4
448	Pretreatment 18F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	7
449	Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. <i>Cancer Medicine</i> , 2021, 10, 4269-4281.	1.3	8
450	Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 601722.	1.3	32
451	The Pan-Immune-Inflammation Value in microsatellite instabilityâ€“high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 150, 155-167.	1.3	45
452	Treatment sequencing of metastatic colorectal cancer based on primary tumor location. <i>Seminars in Oncology</i> , 2021, 48, 119-129.	0.8	4
453	Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies. <i>Drugs and Aging</i> , 2021, 38, 639-654.	1.3	1
454	Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study. <i>Cancers</i> , 2021, 13, 2966.	1.7	11
455	Reliability and validity of Dâ€“dimer monitoring for pulmonary thromboembolism in patients with unresectable, advanced or recurrent colorectal cancer treated with bevacizumab. <i>Molecular and Clinical Oncology</i> , 2021, 15, 165.	0.4	1
456	Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxiaâ€“inducible factorâ€“1 α in colorectal cancer. <i>Molecular Oncology</i> , 2021, 15, 3513-3526.	2.1	20
457	Tumor suppressor miRâ€“193aâ€“3p enhances efficacy of BRAF/MEK inhibitors in <i>BRAF</i>-mutated colorectal cancer. <i>Cancer Science</i> , 2021, 112, 3856-3870.	1.7	9
458	Cliniciansâ€™ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, â€œReal-Lifeâ€œ, Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	8
459	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021, 125, 839-845.	2.9	9
460	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3504.	1.7	5
461	Efficacy of perioperative chemotherapy in resected colorectal liver metastasis: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 3113-3122.	0.5	8

#	ARTICLE	IF	CITATIONS
462	Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time. <i>Pharmaceuticals</i> , 2021, 14, 639.	1.7	6
463	Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience. <i>Cancers</i> , 2021, 13, 3863.	1.7	6
464	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KKR 0306; FIRE $\hat{=}$ 3). <i>International Journal of Cancer</i> , 2021, 149, 1935-1943.	2.3	3
465	BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options. <i>Der Pathologe</i> , 2021, 42, 98-109.	0.7	5
466	Complete Pathologic Response of Multiple Liver Metastases and Clinical Complete Response of Rectal Cancer in a Patient with Ataxia-Telangiectasia Mutated Gene Mutations After XELOXIRI Plus Bevacizumab: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4201-4209.	1.0	2
467	The Comparison of Fecal Microbiota in Left-Side and Right-Side Human Colorectal Cancer. <i>European Surgical Research</i> , 2021, 62, 248-254.	0.6	15
468	BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 705060.	1.8	20
469	Ternary Copper (II) Complex Induced Apoptosis and Cell Cycle Arrest in Colorectal Cancer Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 999-1011.	0.9	4
470	Inflammation-Related Biomarkers for the Prediction of Prognosis in Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8002.	1.8	166
471	Molecular Determinants and Other Factors to Guide Selection of Patients for Hepatic Resection of Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 82.	1.3	5
473	Modern strategy for treatment of metastatic colorectal cancer as key to increasing life expectancy of patients with metastatic colorectal cancer without mutations in RAS genes. <i>Medical Alphabet</i> , 2021, , 54-63.	0.0	1
474	Pharmacogenetic markers of chemotherapy toxicity in gastrointestinal tumors: a preliminary analysis. <i>Journal of Modern Oncology</i> , 2021, 23, 314-318.	0.1	0
475	Borderline resectable for colorectal liver metastases: Present status and future perspective. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 756-763.	0.8	7
476	Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial). <i>International Journal of Colorectal Disease</i> , 2021, 36, 2637-2647.	1.0	1
477	The $\hat{=}$ Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan (CPT-11), Oxaliplatin (LOHP), Continuous Infusion 5-Fluorouracil, and Leucovorin for Colorectal Cancer $\hat{=}$. <i>Gastroenterology Report</i> , 2021, 9, 279-289.	0.6	3
478	<i>KRAS</i> mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1325-1334.	1.4	4
479	No benefit after neoadjuvant chemoradiation in stage IV rectal cancer: A propensity score-matched analysis on a real-world population. <i>Digestive and Liver Disease</i> , 2021, 53, 1041-1047.	0.4	3
480	NeRAS wild-type in metastatic colorectal cancer: Myth or truth? $\hat{=}$ Case series and review of the literature. <i>European Journal of Cancer</i> , 2021, 153, 86-95.	1.3	16

#	ARTICLE	IF	CITATIONS
481	Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward. <i>Cancers</i> , 2021, 13, 3926.	1.7	25
482	Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. <i>Annals of Oncology</i> , 2021, 32, 959-967.	0.6	102
483	Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report. <i>Neuropeptides</i> , 2021, 88, 102160.	0.9	3
484	Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1509-1517.	0.6	3
485	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBES2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	1.3	5
486	Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. <i>Cancers</i> , 2021, 13, 4590.	1.7	7
487	The best strategy for metastatic colorectal cancer(mCRC) patients in second-line treatment: A network meta-analysis. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100455.	0.7	6
488	Real-World Outcomes of Oxaliplatin-Based Chemotherapy on R0 Resected Colonic Liver Metastasis. <i>Clinical Colorectal Cancer</i> , 2021, 20, e201-e209.	1.0	0
489	<i>KRAS</i> and <i>BRAF</i> Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 517-527.	3.0	34
490	Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124766.	2.8	2
491	Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice. <i>Pathology and Oncology Research</i> , 2021, 27, 1609963.	0.9	2
492	Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab. <i>Frontiers in Oncology</i> , 2021, 11, 736104.	1.3	8
493	<i>BRAF</i> V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases. <i>Cancer Medicine</i> , 2021, 10, 6998-7011.	1.3	7
494	Pharmacotherapy for unresectable metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, , 1-10.	0.9	1
495	Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. <i>Cancers</i> , 2021, 13, 4506.	1.7	11
496	Chemotherapy of metastatic colon cancer in France: A population-based study. <i>Digestive and Liver Disease</i> , 2021, 53, 1334-1342.	0.4	2
497	Improving regorafenib's organ target precision via nano-assembly to change its delivery mode abolishes chemoresistance and liver metastasis of colorectal cancer. <i>Journal of Colloid and Interface Science</i> , 2022, 607, 229-241.	5.0	5
498	Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study. <i>BMC Cancer</i> , 2021, 21, 30.	1.1	2

#	ARTICLE	IF	CITATIONS
499	Network Meta-analysis of First-Line Systemic Treatment for Patients With Metastatic Colorectal Cancer. <i>Cancer Control</i> , 2021, 28, 107327482110334.	0.7	3
500	PEG-poly(amino acid)s/EpCAM aptamer multifunctional nanoparticles arrest the growth and metastasis of colorectal cancer. <i>Biomaterials Science</i> , 2021, 9, 3705-3717.	2.6	13
501	<i>BRAF</i> , <i>MEK</i> and <i>EGFR</i> inhibition as treatment strategies in <i>BRAF</i> V600E metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199297.	1.4	38
504	Vaccine Therapy in Pancreatic Cancer. , 2018, , 281-307.		1
505	Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on <i>BRAF</i> status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO) Tj ETQq0 0 0 rgBT70verlock610 Tf 50 5	1.2	6
506	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. <i>European Journal of Cancer</i> , 2020, 133, 66-73.	1.3	19
507	Metformin selectively inhibits metastatic colorectal cancer with the <i>KRAS</i> mutation by intracellular accumulation through silencing MATE1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 13012-13022.	3.3	47
508	ALPPS Improves Survival Compared With TSH in Patients Affected of CRLM. <i>Annals of Surgery</i> , 2021, 273, 442-448.	2.1	101
509	Integrative Gene Expression Profiling Analysis to Investigate Potential Prognostic Biomarkers for Colorectal Cancer. <i>Medical Science Monitor</i> , 2020, 26, e918906.	0.5	20
510	Prognostic Role of <i>BRAF</i> Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials. <i>PLoS ONE</i> , 2016, 11, e0154795.	1.1	22
511	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0182512.	1.1	27
512	CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis. <i>Aging</i> , 2020, 12, 16270-16293.	1.4	19
513	Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis. <i>Oncotarget</i> , 2017, 8, 62339-62348.	0.8	7
514	Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). <i>Oncotarget</i> , 2017, 8, 105749-105760.	0.8	41
515	A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. <i>Oncotarget</i> , 2018, 9, 18811-18820.	0.8	27
516	Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors. <i>Oncotarget</i> , 2018, 9, 35251-35265.	0.8	6
517	Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study. <i>Oncotarget</i> , 2018, 9, 33702-33709.	0.8	6
518	Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 46678-46691.	0.8	35

#	ARTICLE	IF	CITATIONS
519	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 12.	0.5	5
520	Colorectal cancer genomics and designing rational trials. <i>Annals of Translational Medicine</i> , 2018, 6, 159-159.	0.7	19
521	Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 36-44.	0.7	9
523	Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 730-740.	1.0	24
524	Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer. <i>Anticancer Research</i> , 2018, 38, 1427-1434.	0.5	3
525	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , 2019, 8, e11545.	0.5	27
526	KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician. <i>Radiology and Oncology</i> , 2019, 53, 265-274.	0.6	88
527	Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy. <i>World Journal of Gastroenterology</i> , 2016, 22, 9378.	1.4	34
528	Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound. <i>World Journal of Gastroenterology</i> , 2017, 23, 2899.	1.4	6
529	Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. <i>World Journal of Gastroenterology</i> , 2017, 23, 1406.	1.4	22
530	Therapeutic options for peritoneal metastasis arising from colorectal cancer. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 343.	0.6	18
531	First-line treatment with modified FOLFOXIRI plus bevacizumab in patients with locally advanced colorectal cancer. <i>Annals of Cancer Research and Therapy</i> , 2020, 28, 44-48.	0.1	1
532	Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2019, 10, 75-85.	0.9	7
533	Signet ring cell carcinoma of the gastrointestinal tract: National trends on treatment effects and prognostic outcomes. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100475.	0.7	5
534	GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 117-129.	0.4	6
535	The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 724883.	2.2	19
536	Genomic landscape of treatment refractory metastatic colorectal cancer. <i>Acta Oncologica</i> , 2021, 60, 1621-1628.	0.8	2
537	Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment. <i>Cancers</i> , 2021, 13, 5080.	1.7	8

#	ARTICLE	IF	CITATIONS
538	Colorectal cancer liver metastases: An update of treatment strategy and future perspectives. <i>Surgery in Practice and Science</i> , 2021, 7, 100042.	0.2	1
539	Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment. <i>Case Reports in Oncology</i> , 2021, 14, 1475-1482.	0.3	1
540	Difficulties and Challenges in the Management of Market Access for Innovative Oncological Therapies. <i>Global & Regional Health Technology Assessment</i> , 2016, 3, GRHTA.5000237.	0.2	0
541	CHEMOTHERAPY IN THE MANAGEMENT OF LOCALIZED AND METASTATIC COLON CANCER: NEW AND YET UNFORGOTTEN APPROACHES. <i>Meditinskiy Sovet</i> , 2017, , 67-76.	0.1	2
542	Kolorektales Karzinom. , 2018, , 273-341.		0
543	The application of the modern target medications for the treatment of metastatic colorectal cancer. <i>Russian Journal of Evidence-Based Gastroenterology</i> , 2018, 7, 21.	0.3	1
544	Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. , 2018, , 245-260.		0
545	Kolon. , 2018, , 181-225.		0
546	Induktive präoperative Chemotherapie bei peritonealen Metastasen von Tumoren des unteren GI-Trakts inkl. Appendixkarzinom. , 2018, , 73-82.		0
547	Recent Progress in First-Line Chemotherapy in Metastatic Colorectal Cancer. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2018, 71, 371-379.	0.1	0
548	Intensification thérapeutique dans la prise en charge du cancer colorectal métastatique : trichimiothérapie systémique et traitements intra-artériels hépatiques. <i>Colon and Rectum</i> , 2018, 12, 170-177.	0.0	0
549	Classifications moléculaires et immunes des cancers colorectaux : implication pour la prise en charge clinique. <i>Colon and Rectum</i> , 2018, 12, 138-144.	0.0	0
550	Traitement du cancer colorectal métastatique : ciblage moléculaire. <i>Colon and Rectum</i> , 2018, 12, 178-183.	0.0	0
552	New therapeutic agents for metastatic colorectal cancer: literature review. <i>OnkologiĚeskaĚ KoloproktologiĚ</i> , 2018, 8, 34-46.	0.1	0
553	Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. , 2019, , 379-394.		0
554	Metastatic Colorectal Cancer. , 2019, , 135-160.		0
555	Faut-il prendre en compte la localisation du primitif dans la prise en charge du cancer colorectal métastatique ?. <i>Colon and Rectum</i> , 2019, 13, 104-107.	0.0	0
556	The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-line Chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2891-2896.	0.5	0

#	ARTICLE	IF	CITATIONS
557	Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?. <i>Annals of Translational Medicine</i> , 2019, 7, 601-601.	0.7	0
558	Conversion Chemotherapy for CRLM-Best Associations, and Does Conversion Translate into Longer Survival?. , 2020, , 239-247.		0
559	Prognosis and Management of Recurrent Metastatic Colorectal Cancer. , 2020, , 571-587.		0
560	Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2019, 7, 4244-4249.	0.1	2
561	Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 5472.	1.7	0
562	Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11780.	1.8	7
563	FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis. <i>Meditsinskiy Sovet</i> , 2020, , 125-132.	0.1	1
564	The Effect of Tumor Sideness and Mutational Status on First Line Treatment Response and Survival in The Patients with Metastatic Colorectal Cancer. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2020, 30, 197-206.	0.1	0
565	Cancer Treatment Modalities Systemic and Locoregional Approaches: Challenges and Opportunities of Multidisciplinary Approaches. , 2021, , 17-37.		1
566	A roadmap for medical treatment of metastatic CRC. , 2022, , 365-379.		0
567	Glimmers of Hopeâ€”New Strategies for Overcoming Treatment Resistance in Patients with <i>BRAF</i> V600E-mutated Metastatic Colorectal Cancer. <i>Oncology & Hematology Review</i> , 2020, 16, 31.	0.2	1
568	Optimum patient selection for irinotecan-containing regimens in metastatic colorectal cancer: Literature review and lessons from clinical practice. <i>Indian Journal of Cancer</i> , 2020, 58, 5-16.	0.2	2
569	Advancement of clinical therapeutic research on glioma: A narrative review. <i>Glioma (Mumbai, India)</i> , 2020, 3, 119.	0.0	1
570	BAF57 Is a Potential Determinant of Colorectal Cancer Malignancy. <i>Anticancer Research</i> , 2021, 41, 5445-5452.	0.5	1
572	Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?. <i>Current Oncology Reports</i> , 2021, 23, 140.	1.8	3
573	Emerging Treatment Options for the Management of Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 949-952.	2.3	0
574	Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, 707-708.	0.7	0
575	Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 1080-1090.	0.8	6

#	ARTICLE	IF	CITATIONS
576	Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer. , 2021, , 187-202.		0
578	High expression of NSUN5 promotes cell proliferation via cell cycle regulation in colorectal cancer. American Journal of Translational Research (discontinued), 2020, 12, 3858-3870.	0.0	6
579	Chiauranib selectively inhibits colorectal cancer with wild-type by modulation of ROS through activating the p53 signaling pathway. American Journal of Cancer Research, 2020, 10, 3666-3685.	1.4	2
580	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. Cancer Treatment Reviews, 2022, 102, 102301.	3.4	17
581	Comparison of safety and efficacy of fluorouracil+oxaliplatin+irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice. International Journal of Colorectal Disease, 2022, 37, 337-348.	1.0	4
582	Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data. Cancers, 2021, 13, 6018.	1.7	3
583	Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. Frontiers in Oncology, 2021, 11, 764912.	1.3	10
584	Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology, 2022, 29, 3405-3417.	0.7	16
585	Treatment of relapse and survival outcomes after liver transplantation in patients with colorectal liver metastases. Transplant International, 2021, 34, 2205-2213.	0.8	13
586	mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis. Clinical Colorectal Cancer, 2022, 21, e12-e20.	1.0	6
587	Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01). Anticancer Research, 2021, 41, 6247-6257.	0.5	1
588	The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Frontiers in Immunology, 2021, 12, 792691.	2.2	39
589	Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. Future Oncology, 2021, 17, 5013-5022.	1.1	2
590	Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. British Journal of Cancer, 2022, 126, 1264-1270.	2.9	15
591	Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. Cancer Treatment Reviews, 2022, 103, 102326.	3.4	6
592	Abnormal angiogenesis associated with HIF-1 \pm /VEGF signaling pathway in recurrent miscarriage along with therapeutic goals. Gene Reports, 2022, 26, 101483.	0.4	3
593	Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. Digestive and Liver Disease, 2022, 54, 324-330.	0.4	5
594	Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers. Asia-Pacific Journal of Clinical Oncology, 2022, , .	0.7	1

#	ARTICLE	IF	CITATIONS
595	Precision medicine for metastatic colorectal cancer in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110727.	1.4	23
596	A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea. <i>Healthcare (Switzerland)</i> , 2022, 10, 218.	1.0	1
597	BRAF V600E mutations in right-side colon cancer: Heterogeneity detected by liquid biopsy. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1375-1383.	0.5	6
598	Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial. <i>European Journal of Cancer</i> , 2022, 163, 152-162.	1.3	7
599	Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 235-247.	1.9	3
600	Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going. <i>Clinical Colorectal Cancer</i> , 2022, 21, 71-79.	1.0	4
601	Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial. <i>ESMO Open</i> , 2022, 7, 100391.	2.0	6
602	Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 756214.	1.3	7
603	Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 144-150.	2.3	4
604	The sequence of antiVEGF(R) preparations in the treatment of metastatic colorectal carcinoma in 2020. <i>Onkologie (Czech Republic)</i> , 2021, 14, 263-267.	0.0	0
605	Prognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
606	A Case of Pathological Complete Remission for Colon Cancer with <i>BRAF</i> V600E Mutation and MSI-high Plus Multiple Metastasis by Pembrolizumab after Bevacizumab Plus FOLFOXIRI Therapy. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2022, 75, 182-187.	0.1	0
608	Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 663-672.	0.9	3
609	Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management. <i>Current Oncology</i> , 2022, 29, 1223-1236.	0.9	9
610	mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial. <i>Annals of Translational Medicine</i> , 2022, 10, 171-171.	0.7	5
611	Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases. <i>Annals of Surgical Oncology</i> , 2022, 29, 3593-3603.	0.7	3
612	The Evolving Neoadjuvant Treatment Paradigm for Patients with Locoregional mismatch Repair Proficient Rectal Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 453-473.	1.3	4
613	Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge. <i>Current Oncology Reports</i> , 2022, 24, 943-950.	1.8	3

#	ARTICLE	IF	CITATIONS
614	Management of chemotherapy dose intensity for metastatic colorectal cancer (Review). <i>Oncology Letters</i> , 2022, 23, 141.	0.8	1
615	Identification and validation of a seven-gene prognostic marker in colon cancer based on single-cell transcriptome analysis. <i>IET Systems Biology</i> , 2022, 16, 72-83.	0.8	4
616	Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	0
617	Prognostic significance of peritoneal metastasis from colorectal cancer treated with first-line triplet chemotherapy. <i>World Journal of Clinical Cases</i> , 2022, 10, 2429-2438.	0.3	0
618	UGT1A1 Allele Test Not Only Minimizes the Toxicity But Also Maximizes the Therapeutic Effect of Irinotecan in the Treatment of Colorectal Cancer: A Narrative Review. <i>Frontiers in Oncology</i> , 2022, 12, 854478.	1.3	2
619	Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101856.	0.7	1
621	IL25 Enhanced Colitis-Associated Tumorigenesis in Mice by Upregulating Transcription Factor GLI1. <i>Frontiers in Immunology</i> , 2022, 13, 837262.	2.2	6
622	FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. <i>Journal of Clinical Pathology</i> , 2023, 76, 548-554.	1.0	1
623	Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments. <i>Cancers</i> , 2022, 14, 1800.	1.7	7
624	Current Updates on HER2-Directed Therapies in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2022, 18, 27.	1.0	0
625	FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 359.	1.1	1
626	Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 1522-1530.	1.6	3
627	Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series. <i>Clinical Colorectal Cancer</i> , 2022, 21, 267-271.	1.0	5
628	FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial. <i>Frontiers in Oncology</i> , 2021, 11, 766500.	1.3	12
629	First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASC01 study. <i>British Journal of Cancer</i> , 2022, 126, 1548-1554.	2.9	4
630	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGE0-GONO case series. <i>European Journal of Cancer</i> , 2022, 168, 34-40.	1.3	4
634	Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial. <i>BMJ Open</i> , 2022, 12, e049992.	0.8	3
636	Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy. <i>Biomedicines</i> , 2022, 10, 1035.	1.4	5

#	ARTICLE	IF	CITATIONS
637	Thermal ablation in the management of oligometastatic colorectal cancer. <i>International Journal of Hyperthermia</i> , 2022, 39, 627-632.	1.1	5
638	The Evolving Treatment Landscape in <i>BRAF-V600E</i> -Mutated Metastatic Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 254-263.	1.8	13
639	Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401.	157.7	167
640	Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. <i>Targeted Oncology</i> , 2022, , 1.	1.7	1
641	Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. <i>BMC Medicine</i> , 2022, 20, 155.	2.3	9
642	Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study. <i>European Journal of Cancer</i> , 2022, 169, 166-178.	1.3	0
643	Microsatellite Instability and Metastatic Colorectal Cancer – A Clinical Perspective. <i>Frontiers in Oncology</i> , 2022, 12, 888181.	1.3	14
645	Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 1-12.	1.8	12
646	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 876-887.	5.1	83
647	Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study. <i>British Journal of Cancer</i> , 2022, 127, 686-694.	2.9	4
648	Pertuzumab Plus Trastuzumab for Treatment-Refractory <i>HER2</i> -Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	1.0	3
649	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	2.9	6
650	Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?. <i>Drugs and Therapy Perspectives</i> , 0, , .	0.3	0
652	Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy. <i>Future Oncology</i> , 0, , .	1.1	1
653	Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1. <i>Immunotherapy</i> , 0, , .	1.0	8
654	Encorafenib plus cetuximab for the treatment of <i>BRAF-V600E</i> -mutated metastatic colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211106.	1.4	4
655	Research Progress on the Difference between Left and Right Colon Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 5999-6006.	0.0	0
656	Neoadjuvant Mfolfoxiri With Selective Radiotherapy in Locally Advanced Rectal Cancer: Long-term Outcomes of Phase II Study and Propensity-Score Matched Comparison With Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 0, Publish Ahead of Print, .	0.7	1

#	ARTICLE	IF	CITATIONS
657	Practical Considerations in Diagnosing and Managing Early-Onset GI Cancers. <i>Journal of Clinical Oncology</i> , 2022, 40, 2662-2680.	0.8	7
658	Efficacy in randomised trials: the time matters. <i>Lancet Oncology</i> , The, 2022, 23, 839-840.	5.1	0
659	The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. <i>Future Oncology</i> , 2022, 18, 2733-2744.	1.1	1
660	Prognostic and predictive molecular biomarkers in advanced colorectal cancer. , 2022, 236, 108239.		17
661	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	1.3	14
662	Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. <i>International Immunopharmacology</i> , 2022, 110, 108968.	1.7	2
663	Role of Neoadjuvant therapy in the treatment of patients with colorectal liver metastases. , 2023, , 81-99.		0
664	Immunotherapy and targeted therapies for colorectal liver metastasis. , 2023, , 231-246.		0
665	Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
666	Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1439-1449.	1.0	0
667	Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: short-term and long-term outcomes from the CHECK study â€” protocol for a randomised, multicentre, phase 3 trial. <i>BMJ Open</i> , 2022, 12, e051324.	0.8	2
668	DEPDC1B promotes colorectal cancer via facilitating cell proliferation and migration while inhibiting apoptosis. <i>Cell Cycle</i> , 2023, 22, 131-143.	1.3	3
669	Colon Cancer Pharmacogenetics: A Narrative Review. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 95.	0.6	7
670	Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
671	WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-institutional Registry-based Study (BRACELET Study). <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	0
672	Hospital factors and metastatic surgery in colorectal cancer patients, a population-based cohort study. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
673	The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 49-71.	157.7	23
674	Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. , 2022, 33, 627-663.		0

#	ARTICLE	IF	CITATIONS
675	BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 4067.	1.7	5
676	First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer â€œ Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110). <i>European Journal of Cancer</i> . 2022, 173, 194-203.	1.3	0
677	Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM). <i>ESMO Open</i> , 2022, 7, 100567.	2.0	9
678	Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. <i>European Journal of Cancer</i> , 2022, 175, 136-157.	1.3	76
679	PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma. <i>Genes</i> , 2022, 13, 1535.	1.0	0
680	Molecular profiling in colorectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 206-210.	0.3	1
681	Optimal Surgical Indications for Resectable Metastatic Colorectal Cancer with BRAF V600E Mutation. <i>Japanese Journal of Gastroenterological Surgery</i> , 2022, 55, 473-482.	0.0	0
682	Prognostic factors and individualized nomograms predicting overall survival in stage IV rectal cancer patients with different metastatic status: a SEER-based study. <i>Translational Cancer Research</i> , 2022, 11, 3141-3155.	0.4	1
683	RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. <i>Nature Medicine</i> , 2022, 28, 2162-2170.	15.2	39
684	Multicentre single-arm phase II trial evaluating the safety and efficacy of Panitumumab and irinotecan in NeORAS Wild-type metastatic colorectal cancer patients (C-PROWESS trial): study protocol. <i>BMJ Open</i> , 2022, 12, e063071.	0.8	6
685	The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
686	Assessing Oncologistsâ€™ Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real World Data. <i>JNCI Cancer Spectrum</i> , 0, , .	1.4	2
687	FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases. <i>Annals of Translational Medicine</i> , 2022, 10, 952-952.	0.7	1
690	Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk (â€œuglyâ€) locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT). <i>BMC Cancer</i> , 2022, 22, .	1.1	3
691	The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases. <i>Surgery</i> , 2022, 172, 1434-1441.	1.0	0
692	The Practical Application of Cancer Genomic-based Medicine in Colorectal Cancer. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2022, 75, 461-467.	0.1	0
693	The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer. <i>Life</i> , 2022, 12, 1552.	1.1	0
694	Reexposici3n de la terapia con Anti-EGFR en pacientes con c4ncer colorrectal metast4sico RAS/BRAF tipo salvaje. , 2022, 26, .		0

#	ARTICLE	IF	CITATIONS
695	Colorectal Cancer and Purinergic Signalling: An Overview. <i>Cancers</i> , 2022, 14, 4887.	1.7	6
696	PET-Uptake in Liver Metastases as Method to Predict Tumor Biological Behavior in Patients Transplanted for Colorectal Liver Metastases Developing Lung Recurrence. <i>Cancers</i> , 2022, 14, 5042.	1.7	2
697	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
698	The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis. <i>Oncologist</i> , 2022, 27, 1034-1040.	1.9	6
699	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
700	Treatment of Metastatic Colorectal Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2023, 41, 678-700.	0.8	110
701	A New Source of Heterogeneity in Comparative and Translational Clinical Trials: The "Border-Time" Bias. <i>Cancers</i> , 2022, 14, 5265.	1.7	0
702	Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 10-32.	0.6	316
703	Association between a single nucleotide polymorphism in the <i>R3HCC1</i> gene and irinotecan toxicity. <i>Cancer Medicine</i> , 2023, 12, 4294-4305.	1.3	3
704	Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	1
705	Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials. <i>ESMO Open</i> , 2022, 7, 100606.	2.0	1
706	Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. <i>Journal of Clinical Oncology</i> , 2023, 41, 460-471.	0.8	16
707	Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
709	Conversion Strategy in Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study. <i>Cancers</i> , 2022, 14, 5513.	1.7	3
710	Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study. <i>ESMO Open</i> , 2022, 7, 100603.	2.0	5
711	Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond. , 2022, , 293-299.		0
712	Initial Systemic Chemotherapy for Metastatic Colorectal Cancer. , 2022, , 279-286.		0
713	Treatment Options in BRAF-mutant Metastatic Colorectal Cancer. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 103.	0.1	0

#	ARTICLE	IF	CITATIONS
714	Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>JCO Precision Oncology</i> , 2022, , .	1.5	7
715	ACR Appropriateness Criteria® Management of Liver Cancer: 2022 Update. <i>Journal of the American College of Radiology</i> , 2022, 19, S390-S408.	0.9	1
716	Targeting BRAF V600E in metastatic colorectal cancer: where are we today?. <i>Ecancermedicalsecience</i> , 0, 16, .	0.6	1
717	The prognostic index of m7G-related genes in CRC correlates with immune infiltration. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
718	Synchronous liver and peritoneal metastases from colorectal cancer: Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection a feasible option?. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	3
719	Risk of Thromboembolic Events and Major Adverse Cardiovascular Events Following Antivascular Endothelial Growth Factor Therapy in Patients with Colorectal Cancer. <i>Cancers</i> , 2023, 15, 9.	1.7	1
720	Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 7523.	1.0	1
721	TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III <i>BRAF</i> V600E-mutated colorectal cancer. <i>Future Oncology</i> , 2022, 18, 4153-4160.	1.1	1
722	ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	4
723	Current Targeted Therapy for Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1702.	1.8	22
724	A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study. <i>Clinical Cancer Research</i> , 2023, 29, 1017-1030.	3.2	13
725	Targeting <i>KRAS</i> G12C mutations in colorectal cancer. <i>Gastroenterology Report</i> , 2022, 11, .	0.6	1
726	New developments in targeted therapy for metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211485.	1.4	8
727	Therapeutic landscape and future direction of metastatic colorectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 306-322.	8.2	33
728	Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
729	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. <i>World Journal of Gastroenterology</i> , 0, 29, 926-948.	1.4	4
730	Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 1017-1030.	0.6	3
731	Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab. <i>Scientific Reports</i> , 2023, 13, .	1.6	2

#	ARTICLE	IF	CITATIONS
732	ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i> ^{V600E} -Mutant Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 2628-2637.	0.8	25
733	Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review. <i>Current Oncology Reports</i> , 2023, 25, 341-352.	1.8	2
734	<i>BRAF</i> V600E and <i>RNF43</i> Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer. <i>Oncologist</i> , 2023, 28, e171-e174.	1.9	5
735	FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer. <i>ESMO Open</i> , 2023, 8, 100883.	2.0	1
736	CACA guidelines for holistic integrative management of rectal cancer. , 2023, 2, .		0
737	Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. <i>Nature Medicine</i> , 2023, 29, 605-614.	15.2	27
738	Real-world treatment and outcomes of patients with metastatic <i>BRAF</i> mutant colorectal cancer. <i>Cancer Medicine</i> , 2023, 12, 10473-10484.	1.3	5
739	Plasmatic <i>BRAF</i> -V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with <i>BRAF</i> combinatorial treatments. <i>Annals of Oncology</i> , 2023, 34, 543-552.	0.6	15
740	Effectiveness of Standard Treatment for Stage 4 Colorectal Cancer: Traditional Management with Surgery, Radiation, and Chemotherapy. <i>Clinics in Colon and Rectal Surgery</i> , 2024, 37, 062-065.	0.5	0
741	The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1 st line treatment of metastatic colorectal (mCRC) patients with <i>RAS</i> wild-type tumour (wt <i>RAS</i>) – a real-life data report 2013–2018. <i>Radiology and Oncology</i> , 2023, 57, 103-110.	0.6	1
742	Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program. <i>JCO Precision Oncology</i> , 2023, , .	1.5	2
743	Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan. <i>Journal of Medical Economics</i> , 2023, 26, 614-626.	1.0	0
782	Colorectal cancer heterogeneity and targeted therapy: clinical implications, challenges, and solutions for treatment resistance. , 2023, , 207-221.		0